These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 21447724)

  • 61. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
    Kwekkeboom DJ; Kooij PP; Bakker WH; Mäcke HR; Krenning EP
    J Nucl Med; 1999 May; 40(5):762-7. PubMed ID: 10319747
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Feasibility of experimental BT4C glioma models for somatostatin receptor 2-targeted therapies.
    Kiviniemi A; Gardberg M; Autio A; Li XG; Heuser VD; Liljenbäck H; Käkelä M; Sipilä H; Kurkipuro J; Ylä-Herttuala S; Knuuti J; Minn H; Roivainen A
    Acta Oncol; 2014 Aug; 53(8):1125-34. PubMed ID: 24957558
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Impact of Multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors.
    Ruf J; Heuck F; Schiefer J; Denecke T; Elgeti F; Pascher A; Pavel M; Stelter L; Kropf S; Wiedenmann B; Amthauer H
    Neuroendocrinology; 2010; 91(1):101-9. PubMed ID: 19996582
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cancer with unknown primary: finding a needle in a hay stack.
    Giesel FL; Mehndiratta A; Mafomane MP; Zechmann CM; Bergmann F; Schemmer P; Haberkorn U; Kratochwil C
    Exp Oncol; 2012; 34(1):64-5. PubMed ID: 22453152
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient.
    Kulkarni HR; Schuchardt C; Baum RP
    Recent Results Cancer Res; 2013; 194():551-9. PubMed ID: 22918782
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Time Evolution of DOTATOC Uptake in Neuroendocrine Tumors in View of a Possible Application of Radioguided Surgery with β- Decay.
    Collamati F; Bellini F; Bocci V; De Lucia E; Ferri V; Fioroni F; Grassi E; Iori M; Marafini M; Morganti S; Paramatti R; Patera V; Recchia L; Russomando A; Sarti A; Sciubba A; Senzacqua M; Solfaroli Camillocci E; Versari A; Voena C; Faccini R
    J Nucl Med; 2015 Oct; 56(10):1501-6. PubMed ID: 26338895
    [TBL] [Abstract][Full Text] [Related]  

  • 67. 68Ga-DOTATOC and 18F-FDG PET/CT for identifying the primary lesions of suspected and metastatic neuroendocrine tumors: A prospective study in Taiwan.
    Chen SH; Chang YC; Hwang TL; Chen JS; Chou WC; Hsieh CH; Yeh TS; Hsu JT; Yeh CN; Tseng JH; Chen TC; Yen TC
    J Formos Med Assoc; 2018 Jun; 117(6):480-487. PubMed ID: 28735662
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate.
    Kwekkeboom DJ; Bakker WH; Kam BL; Teunissen JJ; Kooij PP; de Herder WW; Feelders RA; van Eijck CH; de Jong M; Srinivasan A; Erion JL; Krenning EP
    Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):417-22. PubMed ID: 12634971
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
    Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Impact of Ga-68 DOTATOC PET/CT on the diagnosis and treatment of patients with multiple endocrine neoplasia.
    Froeling V; Elgeti F; Maurer MH; Scheurig-Muenkler C; Beck A; Kroencke TJ; Pape UF; Hamm B; Brenner W; Schreiter NF
    Ann Nucl Med; 2012 Nov; 26(9):738-43. PubMed ID: 22865406
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Ectopic Corticotropin-Producing Neuroendocrine Tumor of the Pancreas Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy.
    Makis W; McCann K; Riauka TA; McEwan AJ
    Clin Nucl Med; 2016 Jan; 41(1):50-2. PubMed ID: 26359569
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Treatment of a pituitary metastasis from a neuroendocrine tumour: case report and literature review.
    Goglia U; Ferone D; Sidoti M; Spaziante R; Dadati P; Ravetti JL; Villa G; Bodei L; Paganelli G; Minuto F; Giusti M
    Pituitary; 2008; 11(1):93-102. PubMed ID: 17458701
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Additional information gained by positron emission tomography with (68)Ga-DOTATOC for suspected unknown primary or recurrent neuroendocrine tumors.
    Nakamoto Y; Sano K; Ishimori T; Ueda M; Temma T; Saji H; Togashi K
    Ann Nucl Med; 2015 Jul; 29(6):512-8. PubMed ID: 25894056
    [TBL] [Abstract][Full Text] [Related]  

  • 75. 68Ga-DOTATOC and FDG PET Imaging of Preclinical Neuroblastoma Models.
    Provost C; Prignon A; Cazes A; Combaret V; Delattre O; Janoueix-Lerosey I; Montravers F; Talbot JN
    Anticancer Res; 2016 Sep; 36(9):4459-66. PubMed ID: 27630282
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Exceptional results in neuroendocrine-metastases-caused paraplegia treated with [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC), a radiolabelled somatostatin analogue.
    Waldherr C; Haldemann A; Maecke HR; Crazzolara A; Mueller-Brand J
    Clin Oncol (R Coll Radiol); 2000; 12(2):121-3. PubMed ID: 10853753
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases.
    Limouris GS; Chatziioannou A; Kontogeorgakos D; Mourikis D; Lyra M; Dimitriou P; Stavraka A; Gouliamos A; Vlahos L
    Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1827-37. PubMed ID: 18536916
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Production and quality control of [(90)Y]DOTATOC for treatment of metastatic neuroendocrine tumors: results of 85 syntheses.
    Biasiotto G; Bertagna F; Zanella I; Biasiotto U; Savelli G; Caimi L; Bettinsoli G; Giubbini R; Chinol M
    Nucl Med Commun; 2013 Mar; 34(3):265-70. PubMed ID: 23276826
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Therapy: The role of liquid biopsies to manage and predict PRRT for NETs.
    Kidd M; Modlin IM
    Nat Rev Gastroenterol Hepatol; 2017 Jun; 14(6):331-332. PubMed ID: 28293026
    [No Abstract]   [Full Text] [Related]  

  • 80. Is bone marrow uptake of ⁸⁶Y-DOTATOC routinely observed?
    Walrand S; Pauwels S; Jamar F
    Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1742-3. PubMed ID: 21732104
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.